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Abstract
Background: Peer support interventions can improve carer wellbeing and interventions that engage both the
carer and person with dementia can have significant mutual benefits. Existing research has been criticised for
inadequate rigour of design or reporting. This paper describes the protocol for a complex trial that evaluates one-
to-one peer support and a group reminiscence programme, both separately and together, in a factorial design.
Design: A 2 × 2 factorial multi-site randomised controlled trial of individual peer support and group reminiscence
interventions for family carers and people with dementia in community settings in England, addressing both
effectiveness and cost-effectiveness.
Discussion: The methods described in this protocol have implications for research into psychosocial interventions,
particularly complex interventions seeking to test both individual and group approaches.
Trial Registration: ISRCTN37956201
Background
People with dementia who are cared for by a family
member are less likely to be hospitalised or move into
residential care [1], and have a better quality of life than
those in care homes [2]. However, family carers of peo-
ple with dementia experience greater strain and distress
than carers of other older people [3]. Family carers may
experience social isolation [4] through lack of personal
time and opportunities to socialise, and stigma resulting
in family and friends distancing themselves [5]. Without
support, family carers can feel emotionally and physi-
cally burdened and may experience interrelational con-
flicts, which may reduce perceived level of emotional
support and increase feelings of loneliness [6]. As inter-
ventions delivered by health staff can ‘medicalise’ the
experience of caring and raise stigma [7], interventions
in the voluntary and community sector can provide a
more informal setting for the support of carers. The
World Health Organisation noted the importance of
enhancing social relationships for carers [8], and peer
support for carers is included in the recommendations
of the National Dementia Strategy for England [9]. It
has been suggested that peer support can directly
improve wellbeing by decreasing feelings of isolation
and/or encouraging more appropriate coping strategies,
and enabling a change in behaviour, emotion or cogni-
tions [10]. Hence a body of work is developing to evalu-
ate befriending and peer support interventions.
Befriending and peer support interventions
A recent systematic review of befriending interventions
in healthcare established that befriending has a modest
effect on depressive symptoms. Interventions tend to be
short-term (around 3 months) and are often delivered
by professionals sometimes in collaboration with lay
volunteers [11]. For family carers of people with
* Correspondence: g.charlesworth@ucl.ac.uk
1Research Department of Clinical, Educational, and Health Psychology,
University College London, 1-19 Torrington Place, London, WC1E 7HB, UK
Full list of author information is available at the end of the article
Charlesworth et al. Trials 2011, 12:205
http://www.trialsjournal.com/content/12/1/205 TRIALS
© 2011 Charlesworth et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
dementia neither the effectiveness nor the cost-effective-
ness of befriending or peer support has been established.
A large Randomised Controlled Trial (RCT) of befriend-
ing found modest effects of long-term befriending, but
was not cost-effective [12,13].
However, carers reported that they enjoyed and gained
from the experience, particularly those who were
befriended by former family carers, which highlights the
potential therapeutic effects of peer support. Indeed,
research has found that peer support can help carers in
particularly stressful caring situations [14].
Relationship focused
In contrast to carer-focused interventions there is grow-
ing evidence that carer wellbeing may be enhanced
through interventions that engage both the primary
carer and the person with dementia [15,16], often
described as dyadic interventions. Such interventions
include the ‘Remembering Yesterday Caring Today’
reminiscence group programme [RYCT; [17]] which has
been widely used across Europe and is being evaluated
in a large UK RCT [18].
Aim
The present trial is one of three psychosocial interven-
tions being carried out as part of the Support at Home:
Interventions to Enhance Life in Dementia (SHIELD)
research programme (NIHR grant RP-PG-060-1083).
This trial evaluates the effectiveness and cost-effective-
ness of the SHIELD Carer Supporter Programme (CSP)
and RYCT, both separately and combined. The trial is
described here in accordance with the revised CON-
SORT 2010 reporting requirements [19], as applied to
pragmatic trials [20]. Developing trial designs for com-
plex interventions is challenging, and the MRC guidance
on complex interventions [21] emphasises the impor-
tance of selecting or developing a research design that
can evaluate interventions appropriately and efficiently.
The challenge for this trial was to find a scientifically
valid, but logistically feasible, method for comparing
contrasting interventions where one had an individual
focus, and the other a relationship focus within a group
setting.
Design
The trial is a 2 × 2 factorial single-blind RCT (Figure 1):
the 4 arms of the trial are CSP alone, RYCT alone, CSP
and RYCT combined, and treatment as usual (TAU). To
ensure enough participants to run viable RYCT groups,
we randomise between TAU, RYCT, CSP and combined
in the proportions 1:2:1:2. We collect data at baseline
(post-consent, pre-randomisation), and 5 and 12 months
after the first randomisation, with the main endpoint at
12 months. After randomisation, all participants are free
to continue to receive treatment as usual from statutory
and voluntary services in their locality. We conducted a
feasibility study before the full RCT in accordance with
MRC guidance on complex interventions guidance [21].
The design tests three null hypotheses:
i) There is no effect of CSP compared with TAU
ii) There is no effect of RYCT compared with TAU
iii) There is no interaction between RYCT and CSP
Setting
We are running the trial in community settings in
North East London, Norfolk, Northamptonshire, and
Berkshire.
Participants
Eligibility criteria
All participants are adult (18 years and over) English-
speaking carers for a relative or close friend living at
home in the community with a primary progressive
CSP CSP/RYCT
Informed consent taken from family carers and
persons with dementia
Baseline Assessments conducted
Expressions of interest received.
Screening for eligibility
Individual Randomisation of dyads
CSP TAU
RYCT TAU
2nd Follow up: at end of RYCT monthly reunions in area (approx 12
months after randomisation)
1st Follow up: at end of RYCT weekly sessions (approx 5 months
after randomisation)
Group Randomisation of dyads
Figure 1 Flow diagram of the SHIELD CSP-RYCT trial. A two-
stage sequential dynamic algorithm is used in which participants
are first randomised individually to CSP or TAU and later on a group
basis to RYCT or TAU.
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cognitive impairment or dementia as defined by DSM-
IV criteria for dementia [22]. Carers have to agree to
take part in the full trial (with the right to withdraw
from the research at any time) and for the person they
care for to be approached to take part. Carers are
excluded if they or the person they care for have a con-
genital learning disability or non-progressive brain
injury. Carers with a diagnosed terminal illness are also
excluded as are those already taking part in another psy-
chosocial intervention study.
Recruitment strategy
Recruitment is both direct and indirect to address inher-
ent difficulties in recruiting carers and people with
dementia [23]. Direct recruitment targets participants
within the community using leaflets, flyers and posters.
Strategies for newer and ‘hard-to-reach’ carers include
invitations in local papers and newsletters. Indirect
recruitment uses gatekeepers, like the Alzheimer’s
Society and Admiral Nurses already in contact with the
target population. These gatekeepers tell potential parti-
cipants about the study and distribute recruitment lit-
erature. Contact details of potential participants are only
passed to the research team where consent has been
given for this.
Involving Service User and Carers
We developed the CSP intervention and supporting
related documentation in consultation with service users
and carers [24]. Former and experienced family carers
also have involvement as direct providers of the CSP
element of the trial.
Interventions
Each intervention is organised and provided indepen-
dently of the research assessments.
Peer Support (SHIELD Carer Supporter Programme)
SHIELD CSP gives newer carers access to an adult
Carer Supporter (CS), who is an experienced family
carer or close friend of a person with dementia. The
intervention was originally based on a model of colla-
boration and partnership with a local voluntary carer
support organisation [25]. The research team worked
with a Carer Supporter Manager (CS Manager), based
within a host voluntary sector organisation, to develop
the CSP intervention. There is one Carer Supporter
Coordinator (CS Coordinator) per trial centre who
recruits and screens the CS and is supported by the CS
Manager. In two of the four sites the CSP intervention
is provided by the host NHS organisation, reflecting
‘usual practice’ within their area.
Before being matched with a family carer participant,
CS volunteers attend a mandatory ‘Being a Carer Sup-
porter’ orientation and awareness course led by the CSP
Programme Lead, the CS Manager and/or relevant CS
Coordinator and local health and social care personnel.
The programme has six modules: introducing CSP;
experiences of dementia and caring; the Carer Supporter
role: what it is and what it is not; listening and helping
skills; working in other peoples’ homes; and dementia
awareness for carers and local resources. The CSs must
also agree to abide by the Code of Conduct and State-
ment of Confidentiality.
CSs and family carers are paired through a process of
matching based on demographic factors and personal
preferences, for example the type of dementia they have
experience of, and geographical proximity to one
another. We match pairs to encourage longer and more
satisfying peer support relationships [26]. The role of
the CS is to provide emotional and informational sup-
port to the family carer, offer family carers a listening
ear, and signpost them to local services and other useful
contacts and resources. We ask CSs to support their
family carers for at least one hour per week for the first
three months, and then reduce the frequency to
approximately twice a month for a further seven
months. Contact is face-to-face or over the telephone.
CSs must not carry out tasks that would otherwise be
carried out by a paid worker like nurses or home care
workers, or to give advice or respite care. CSs are sup-
ported by a CS Coordinator throughout the duration of
the match.
Group Reminiscence (Remembering Yesterday, Caring
Today)
The group reminiscence intervention follows the RYCT
programme for people with dementia and their family
carers [17]. Twelve weekly sessions, each lasting two
hours, cover a range of themes including: childhood and
family life; school days; courting and marriage; food and
cooking; and the next generation. Each session explores
its theme using multisensory triggers and activities,
including group discussions, small group activity, object
handling, enacting or improvisation, and singing songs.
The RYCT intervention is provided by either the NHS
host organisation or the host voluntary sector organisa-
tion depending on usual practice in each locality. The
SHIELD programme runs RYCT in community settings
such as church halls, with transport provided if needed.
Each group session is led by two experienced Facilita-
tors, supported by a team, including volunteers, health
and social care staff and trainees to facilitate small
group discussion and activities and engage the people
with dementia. All members of the RYCT team must
attend a training day led by one of the original RYCT
programme authors.
During four of the sessions, the family carers meet
together with one of the Facilitators and another team
member for about 45 minutes, whilst the other Facilita-
tor and remaining team work with the people who have
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dementia. The Carers’ sessions aim to develop listening
and communication skills and consider how the activ-
ities and strategies used within the sessions can be car-
ried over into the home environment. After the 12
initial sessions, monthly reunion sessions take place over
a further seven months using previously successful
themes, or using new themes, depending on the prefer-
ences of the group.
Combined Intervention (SHIELD CSP/RYCT)
The combined intervention offers both contact with a
CS and the opportunity to attend the RYCT pro-
gramme. CSs matched with family carers who have been
randomised to this intervention group are invited to
attend the RYCT sessions, RYCT training with other
volunteers, and a 2-hour training session. The latter
focuses on the purpose of reminiscence and techniques
to encourage reminiscence at home, to enable the CS to
better support the family carer in implementing the
strategies and advice provided within the RYCT Carers’
sessions. The aim of this intervention is to extend the
benefits of RYCT through the CS bringing knowledge of
the care dyad to the group, and then encouraging remi-
niscence in the family carer’s home.
Treatment as usual
The aim of this trial is to examine effectiveness and
cost-effectiveness of interventions over and above usual
care, which varies between sites. Hence participants ran-
domised to the control group continue with any health,
social or voluntary sector services they are currently
receiving or commence once recruited into the trial.
Like the intervention groups, this group is also given a
list of useful resources in their area.
Implementation of Interventions
The MRC Guidance for Developing and Evaluating Com-
plex Interventions [21] recommends that researchers
monitor the extent to which interventions have been deliv-
ered to and received by the participants [27]. We have
designed measures specifically for this trial that capture:
• Treatment Delivery: the extent to which the inter-
vention provider adheres to treatment protocol, the
absence of any other intervention, and the quality of
the intervention
• Treatment Receipt: the extent to which the partici-
pant receives the intervention, the intensity of the
intervention received, and satisfaction with that
intervention.
These data are also entered into a MACRO™
database.
Measures
The primary outcome is health-related quality of life for
the carer. Secondary outcomes for the carer include
psychological well-being, social support, coping and self-
efficacy. Outcomes for the person with dementia include
quality of life, well-being, relationship quality, neuropsy-
chiatric profile, activities of daily living, and cognition.
To explore the active ingredients or mechanisms of
change of the intervention(s) (i.e. how the intervention
might work) [21], we ask family carers about the process
and experience of caring. To explore cost-effectiveness
analysis, we also collect information from them on
resource use and carer time inputs.
Primary outcome
The primary outcome is the family carers’ health-related
quality of life, measured by the validated and widely
used Mental Health Component Summary (MCS-12) of
the UK Short Form-12 Health Survey [UK SF-12; [28]].
The SF-12 measures general health status from the per-
spective of the participant, and in addition to the MCS-
12 also allows for the generation of a second sub-score,
the Physical Component Summary (PCS-12). Reliability
is 0.74 for MCS-12 and 0.78 for PCS-12 [29]. Validity is
0.97 for MCS-12 and 0.67 for PCS-12 [30].
Secondary outcomes
Family carer:
• Health-related quality of life: EQ-5D [31], compris-
ing 5 items and a Visual Analogue Scale (VAS).
• Anxiety and depression: Hospital Anxiety and
Depression Scale [HADS; [32]] comprising 14 items
- 7 for anxiety and 7 for depression.
• Positive and Negative Affect: Positive and Negative
Affect Schedule [PANAS; [33]] comprising two 10-
item scales one measuring positive mood, the other
negative mood.
• Aspects of caring: Carers of Older People in Eur-
ope Index [COPE-Index; [34]] comprising 17 items
measuring carers’ perceptions of their role, positive
and negative aspects of caregiving, and issues of
support.
• Emotional loneliness: the 2-item Loneliness Scale
[35].
• Relationship quality: Quality of Caregiver-Patient
Relationship [QCPR; [36]] comprising 14 items mea-
suring expressed emotion along two dimensions:
level of criticism and level of warmth.
• Coping: Brief-Cope [37] comprising 28 items mea-
suring approaches to coping.
• Self-efficacy: Revised Scale for Caregiving Self Effi-
cacy [RSSE; [38]] comprising 15 items to measure
self-efficacy across three domains.
• Carer distress: Neuropsychiatric Inventory with
Caregiver Distress Scale [NPI-D; [39]] assessing ten
behavioural disturbances associated with dementia.
• Social support: The Positive and Negative Social
Exchanges [PANSE; [40]] comprising 24 items
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measuring the frequency of four domains of positive
and negative social exchanges.
• Social network: Practitioner Assessment of Net-
work Type [PANT; [41]] comprising 8 items that
determine type of supportive network available to
the participant.
• Personal growth: The 3-item version Personal
Growth Index [PGI; [42]].
Person with dementia:
• Health-related quality of life: EQ-5D [31] - as for
family carers, but completed by family carer if per-
son with dementia is unable; this proxy measure
does not include the VAS.
• Anxiety and depression: HADS [32].
• Relationship quality: QCPR [36].
• Quality of life in dementia: Two measures are
administered:
◦ Quality of Life - Alzheimer’s Disease Scale
[QoL-AD; [43]] comprising 13 items namely phy-
sical health, energy, mood, living situation, mem-
ory, family, marriage, friends, chores, fun, money,
self, and life as a whole (also completed by the
carer).
◦ DEMQOL [44] comprising 29 items covering
health, wellbeing, cognitive functioning, social
relationships, and self-concept; the carer also
completes the 31-item proxy version.
• Cognition: Mini-Mental State Examination
[MMSE; [45]] is a widely used rating of cognitive
function. Completed by the person with dementia.
• Activities of daily living: Alzheimer’s Disease Co-
operative Study - Activities of Daily Living Inventory
[ADCS-ADL; [46]] assesses functional capacity
across a number of daily tasks. Completed by the
family carer.
• Global functioning: Clinical Dementia Rating
[CDR; [47]] denoting presence and severity of
dementia. Completed by the research interviewer(s).
Resource Use
The Client Service Receipt Inventory (CSRI) [48] is used
to collect information retrospectively about use of
health, social care and other relevant services, accom-
modation and living situation, benefits, carer support,
and employment. It provides data from which we calcu-
late costs.
Sample size
We based sample size calculations on the BECCA [12]
and REMCARE [18] trials. These predicted effect sizes,
defined as average effect per participant divided by
population standard deviation, of 0.42 for CSP and 0.35
for RYCT. In a 2 × 2 factorial design using a 2:1 alloca-
tion ratio in favour of groups receiving RYCT, a com-
pleted sample of 240 dyads would yield power of more
than 90% to detect both main effects using a signifi-
cance level of 5%. This design would also yield power of
more than 80% to detect interaction between CSP and
RYCT equivalent to an effect size of 0.4, using an analo-
gous definition. As both the REMCARE trial platform
and BECCA retained some 80% of participants, we aim
to recruit 300 dyads in 13 rounds of 24 dyads to yield a
final sample of 240 dyads.
Randomisation
We use a two-stage sequential dynamic algorithm to
allocate individual and group based interventions. We
base the probability of choosing each group on the par-
ticipants’ stratification variables and the previous alloca-
tions for those variables. For the first allocation between
CSP and TAU the stratification variables are locality
and dyad relationship. In the latter, dyads are designated
‘horizontal’ or ‘vertical’ kinship, where horizontal
denotes spouses and siblings and vertical denotes
daughters, sons, daughters-in-law and other similar kin-
ships where there carer and person with dementia are
from different generations within the family. For the
second allocation between RYCT and TAU we add the
first allocation as a stratification variable to keep the
four treatment arms in balance.
The SHIELD administrator enters participants’ vari-
ables into a remote web-based randomisation, which
then allocates them in equal proportions between CSP
or TAU on an individual basis. Once adequate dyads
have been randomised within each site (target 24; range
16-30), the remote randomisation system allocates them
in a second randomisation between RYCT and TAU in
the proportion 2:1 on a group basis. Hence the combi-
nation of these two randomisation stages results in
results in the allocation between TAU, RYCT, CSP, and
RYCT plus CSP in the proportions 1:2:1:2. The
(unblinded) SHIELD administrator then informs carers
of their allocation by letter, and liaises with the RYCT
Facilitator and/or CS Coordinator as appropriate.
Blinding
It is not possible to blind participants or providers to
their allocated intervention in psychosocial interven-
tions. In this trial, for example, both the CS Coordinator
and RYCT Facilitator need to know which carers are
allocated to the combined interventions. However, we
do blind research interviewers who assess outcomes, in
particular by limiting access to the web based manage-
ment system. Research interviewers recorded their per-
ception of participants’ allocations for use as a covariate
in statistical analysis.
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Research Governance
Three formal groups meet regularly to manage the trial
within the SHIELD programme: the Project Manage-
ment Group (PMG); the Programme Steering Commit-
tee (PSC); and the Data Monitoring and Ethics
Committee (DMEC).
Ethical arrangements
Ethical approval was given by the Outer North East Lon-
don Research Ethics Committee (09/H0701/54). In line
with Good Clinical Practice, we developed a Standard
Operating Procedure for accurate and timely reporting of
Serious Adverse Events to the Chief Investigator. He
assesses whether either intervention could have caused
each event and, if so, reports to the DMEC as appropriate.
Consent
The main participants are family carers and it is hoped
that their relatives with dementia will also take part.
They each enter the trial only after giving informed con-
sent. We explain the nature of the research to all parti-
cipants and give them at least 24 hours to consider the
study information before seeking consent, stressing that
their care will not change if they choose not to partici-
pate. We also tell the general practitioners (GPs) of all
participants about their participation. If a person with
dementia is considered to lack capacity, research staff,
acting in accordance with the Mental Capacity Act 2005
[49] and the British Psychological Society Code of Ethics
and Conduct [50], seek documented assent from the
family carer. CSs also give informed consent as an
acknowledgement of the CSs’ Code of Conduct and also
because they are participants in a linked project evaluat-
ing the impact of volunteering on the volunteer.
Data management and statistical analysis
Data are entered into Infermed’s MACRO™ Electronic
Data Capture system for clinical trials that allows data
to be both entered and reviewed. Data are managed
within MACRO™ and exported to a statistical software
package for analysis. Multiple imputation with a linear
regression model will be used for imputing missing out-
come data.
Effectiveness analysis
After exporting data to the statistical package SPSS, we
shall follow the general approach of the UK BEAM trial
[51] and analyse relevant outcomes on the basis of treat-
ment allocated to test whether:
A. CSP, alone or in combination with RYCT,
affected family carers and their relatives;
B. RYCT, alone or in combination with CSP, affected
family carers and their relatives;
C. CSP and RYCT interacted in their effects on
these outcomes.
Specifically we shall use multi-level analysis of covar-
iance with outcome at 12 months after initial randomi-
sation as dependent variable and ‘outcome’ at baseline
and length of time on CSP as covariates, to compare:
(A) CSP and combined groups with TAU and RYCT
groups; (B) RYCT and combined groups with TAU and
CSP groups; and (C) combined and TAU groups with
CSP and RYCT groups. We shall also use linear mixed
models to study longitudinal effects at 5 and 12 months.
We shall treat RYCT versus TAU and CSP versus TAU
as fixed effects, together with gender and dyad relation-
ship. We shall treat the effects of locality (including per-
sonnel) and time as random effects and assess the
covariance structure of this. We shall undertake sensitiv-
ity analysis to test whether plausible changes in key vari-
ables such as carers’ ages and relationships to their
relatives with dementia would have affected findings.
Cost-effectiveness analysis
The primary health economic evaluation will estimate
the incremental cost-effectiveness of:
A. CSP compared with TAU, both alone or both in
combination with RYCT;
B. RYCT compared with TAU, both alone or both in
combination with CSP;
C. CSP and RYCT combined compared with TAU.
These analyses will take a societal perspective, and
measure effectiveness on the MCS-12 [28]. In principle
each cost-effectiveness analysis will have five stages: (a)
measurement of outcomes; (b) measurement of costs;
(c) estimation of incremental cost-effectiveness ratio
(ICER); (d) calculation of net benefits and derivation of
cost-effectiveness acceptability curve (CEAC); (e) and
sensitivity analyses. As these three analyses have many
possible combinations of outcomes we shall follow the
standard economic evaluation approach of extended
dominance.
Outcome estimation
The economic evaluation will employ the same proce-
dures for calculating scores and imputing missing values
as in the primary statistical analyses described above.
Cost estimation
The economic evaluation will use responses on the vali-
dated CSRI [48] completed with the carer. We will
attach nationally relevant unit costs to services used by
participants, using the most recent Personal Social Ser-
vices Research Unit ‘Unit Costs’ volume where available
[52], and costed locally where not, for example for CSP
and RYCT. The time inputs of carers and their lost pro-
ductivity (from giving up or reducing employment) will
be costed using a range of methods to reflect the oppor-
tunity costs to those individuals, and the consequences
of differences explored in sensitivity analyses. The
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primary economic analysis will include costs, both of
service use and of carer inputs (a societal perspective).
We shall compare the outcomes and costs of the four
allocated groups. For example, we shall interpret CSP as
more cost-effective than TAU (both alone or both in
combination with RYCT) if: (i) it is both less costly and
more effective on the MCS-12; or (ii) it is both more
costly and more effective, and the decision maker values
the improvement in outcome at more than the addi-
tional cost; or (iii) it is both less costly and less effective
and the decision-maker attaches lower value to the loss
of outcome than the cost savings. In the fourth option,
when CSP is more costly and less effective than TAU,
the decision maker-would prefer TAU.
To quantify options (ii) and (iii) in this example, we
shall estimate the ICER, namely the mean cost differ-
ence between CSP and TAU (both alone or both in
combination with RYCT) over the follow-up period of
12 months divided by the mean difference between
these groups in the MCS-12 over those 12 months. We
will also estimate net benefit (NB) for each dyad from
the standard formula:
NB = λ× E− C
where:
E is effectiveness, namely the change in the primary
outcome; C is the cost for that dyad (services used by
the carer and the person with dementia, plus indirect
costs of carer time); and l is the decision-maker’s will-
ingness to pay for one additional unit of outcome. After
calculating net benefits for each dyad for plausible
values of l, we shall address the expected skewness in
the distribution of NBs by ‘bootstrapping’; this is the
technique of drawing (say) 10,000 independent replicates
with replacement from the original sample of (say) 240
dyads while keeping the four allocated groups at their
original sizes. For each value of l we shall use these
replicated samples to estimate the true proportion of
dyads whose net benefit is positive, and derive a CEAC
plotting the likelihood of CSP being cost-effective rela-
tive to TAU (both alone or both in combination with
RYCT) against l, the decision-maker’s willingness to
pay. We shall conduct sensitivity analyses to explore the
effect on conclusions of varying key assumptions about
costs and outcomes.
Secondary cost-effectiveness analyses
A number of secondary economic analyses will be
conducted.
The cost-effectiveness analyses set out above (primary
analyses) will be repeated from a health and social care
system perspective, which in this case will mean looking
only at costs to the health and social care system, but
still focusing on MCS-12 as the outcome measure.
We will use the EQ-5D for carers to calculate utility
using societal preference weights, and examine cost-
effectiveness with outcomes measured as utility (quality-
adjusted life years), first from a societal perspective and
then from a health and social care system perspective.
The stages of analysis will match exactly the approach
to be adopted for the primary cost-effectiveness analyses
described above. The results from these analyses will be
in the form of cost per additional quality-adjusted life
year (QALY) and will permit comparison with studies in
other clinical fields and with (for example) NICE
recommendations.
Other outcomes (for carers and people with dementia)
will be examined alongside costs in a series of cost-con-
sequences analyses to cast further light on the impact of
the interventions.
Discussion
The design of the trial is unusual since there are few
psychosocial intervention studies that merit a factorial
design; compare individual, group, and combined inter-
ventions; and undertake a cost-effectiveness analyses,
particularly where the unit of consideration is the dyad
rather than the carer. We know of no examples of fac-
torial studies that assess the impact of interventions on
the mental health of family carers. Hence this pragmatic
trial has the potential to inform and potentially influ-
ence policy and practice not only in relation to care and
treatment for dementia, but also in other chronic mental
and even physical illnesses. The SHIELD CSP-RYCT
trial aims to evaluate peer support focused on both the
carer through CSP and dyad through RYCT. This com-
bination seeks to support the family carers, their rela-
tives with dementia, and the relationship they share.
Supported carers have the potential to care for the per-
son with dementia to provide them with a better quality
of life than those in residential care [2] coupled with
economic advantages.
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